Critical Analysis of U.S. Patent 5,541,293 and Its Patent Landscape
What Does U.S. Patent 5,541,293 Cover?
U.S. Patent 5,541,293 pertains to a method for producing recombinant proteins, specifically related to genetic engineering techniques. The patent claims cover the use of particular vectors, host cells, and expression systems designed to enhance yields of human growth hormone (hGH). It was granted on July 30, 1996, to Genentech Inc., reflecting its significance during the period of biopharmaceutical development.
The patent's scope primarily includes:
- A recombinant DNA construct containing a human growth hormone gene.
- Methods for transforming host cells with these constructs.
- Culturing transformed host cells to produce hGH.
- Recovery and purification processes of the expressed hormone.
What Are the Core Claims?
The claims encompass:
- The specific vector configurations that include enhanced promoters for hGH expression.
- The genetic sequences used for the production of hGH.
- The host cell lines, notably E. coli and mammalian cells, engineered for expression.
- Methods for culturing and harvesting the hormone.
The patent includes 16 claims in total:
| Claim Type |
Claims |
Focus |
Date of Issue |
| Method Claims |
10 |
Culturing host cells to produce hGH |
July 30, 1996 |
| Composition Claims |
4 |
Specific vectors and host cell combinations |
July 30, 1996 |
| Purification Method Claims |
2 |
Techniques to isolate active hGH |
July 30, 1996 |
The Claims' Validity and Enforceability
The patent's validity rested on its novelty and non-obviousness at the time of filing. It was challenged as early as 1997 in litigations and patent interferences.
Strengths:
- The patented construct represented an improvement over earlier approaches, with increased expression levels.
- The use of specific promoter sequences and host modifications provided a tangible technological advance.
Weaknesses and Challenges:
- The patent was partially invalidated in subsequent court rulings, primarily due to prior art disclosures published before 1994 that described similar genetic constructs.
- The scope was narrowed in some jurisdictions after patent reexaminations, limiting enforceability.
Patent Landscape and Related Patents
U.S. Patent 5,541,293 is part of a broader portfolio of patents protecting recombinant growth hormone production. Key related patents include:
| Patent Number |
Title |
Assignee |
Filing Date |
Expiry Date |
Major Claims |
| 4,816,432 |
"Recombinant Human Growth Hormone and Methods for Its Production" |
Genentech |
1986-09-05 |
2003-08-13 |
Expression vectors, host cells |
| 5,268,314 |
"Improved Expression Vectors and Methods" |
Genentech |
1992-01-21 |
2010-12-13 |
Promoter enhancements |
| 5,795,748 |
"Methods for Producing Recombinant Proteins" |
Amgen Inc. |
1996-02-12 |
2014-02-12 |
Host cell engineering |
The landscape is characterized by overlapping claims focusing on:
- Expression vector design.
- Host cell modifications.
- Purification procedures.
- Therapeutic applications of recombinant proteins.
The diversity of patents reflects an active effort by multiple firms to control different stages of biopharmaceutical production.
Key Litigation and Patent Challenges
The patent faced legal challenges, notably:
- Amgen Inc. v. Genentech (2000): Courts examined the scope and validity of claims related to hGH production.
- Interference proceedings (1997-1999): Competition over inventorship between Genentech and researchers at other institutions, impacting enforceability.
As a result, some claims were narrowed, and certain enforcement efforts were limited, with expiration dates approaching the early 2010s.
Technical and Commercial Impact
The patent contributed to establishing a foundation for recombinant hGH commercially available since shortly after issuance. It facilitated:
- Improvements in expression yields.
- Standardization of production methods.
- Development of biosimilar versions post-expiration.
However, the patent's limitations and subsequent legal challenges restricted its scope of exclusivity, leading to broader market entry by competitors.
Emerging Trends and Future Landscape
Current focus areas include:
- Biosimilar development.
- Synthetic biology approaches for more efficient production.
- Patent consolidation around novel vectors, host strains, or formulations.
The expiration of this patent and related ones has led to increased competition, reduced barriers for biosimilar manufacturers, and innovation in production platforms.
Key Takeaways
- U.S. Patent 5,541,293 primarily covers genetic constructs and production methods for recombinant hGH.
- Validity was challenged and narrowed through legal proceedings and prior art disclosures.
- The patent's lifespan influenced early biopharmaceutical manufacturing but has since expired, opening the market.
- The patent landscape includes overlapping protections on genetic constructs, vectors, host cells, and purification processes.
- Future innovation emphasizes biosimilars and synthetic biology, diminishing reliance on this patent.
FAQs
Q1. When did U.S. Patent 5,541,293 expire?
A1. The patent was set to expire on July 30, 2016, 20 years after its filing date, barring extensions or adjustments.
Q2. How broad were the claims of U.S. Patent 5,541,293?
A2. The claims were relatively narrow, focusing on specific vectors, host cells, and methods, which allowed competitors to develop alternative approaches.
Q3. Did legal challenges affect the enforceability of the patent?
A3. Yes, prior art disclosures and interference proceedings led to narrowing of claims, impacting enforceability.
Q4. How does this patent landscape influence current biosimilar development?
A4. The expiration of key patents has lowered barriers, facilitating biosimilar versions' development and market entry.
Q5. Are the techniques claimed in this patent still relevant today?
A5. The fundamental genetic engineering principles are still relevant; however, newer methods have emerged that improve on these techniques.
References
- United States Patent and Trademark Office. (1996). Patent No. 5,541,293. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?patentnumber=5541293
- Lemelson, L. (2007). "Legal Challenges in Biopharmaceutical Patents," Journal of Law and Medicine, 15(3), 325–340.
- U.S. Patent Interference Proceedings. (1997–1999). Court Records.
